<DOC>
	<DOCNO>NCT01153997</DOCNO>
	<brief_summary>This trial conduct Japan . The aim trial investigate safety profile recombinant factor XIII ( rFXIII ) assess occurrence adverse event healthy Japanese subject . In addition pharmacokinetic parameter investigate .</brief_summary>
	<brief_title>Safety Recombinant Factor XIII ( rFXIII ) Healthy Japanese Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<criteria>Good general health base assessment medical history , physical examination , ECG ( electrocardiogram ) clinical laboratory data screening , judge physician Body mass index ( BMI ) 18.027.0 kg/m2 ( inclusive ) The receipt investigational product coagulation factor protein within 6 month prior trial start ( screen ) Known suspect allergy yeast Known bleed hematologic disorder Significant history alcoholism drug/chemical abuse judge physician positive result alcohol breath test/screen drug trial start ( screen ) Smoking 10 cigarettes/day equivalent Not able willing refrain smoking whenever require trial procedure Habitual excessive consumption methylxanthinecontaining beverage food ( coffee , tea , soft drink cola , chocolate ) judge physician Excessive consumption diet deviate normal diet judge physician Strenuous exercise judge physician within 4 day prior trial start ( screen ) Surgery trauma significant blood loss ( 500 mL blood ) within 3 month prior trial start ( screen ) Males sexually active surgically sterilise , whose partner use adequate contraceptive method . Adequate contraceptive measure include subject us condom intercourse partner practice adequate conception ( sterilisation , hormonal intrauterine device oral contraceptive ) .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>